论文部分内容阅读
目的观察左炔诺孕酮宫内缓释系统(曼月乐)治疗子宫腺肌症的临床效果。方法选择医院2013年6月-2015年8月采用曼月乐治疗的子宫腺肌症患者27例,随访1年,观察患者治疗前后月经、子宫、血清CA125及相关不良反应情况。结果与治疗前相比,治疗3、6、12个月Cox痛经症状量表(CMSS)评分、月经失血图(PBAC)评分、子宫内膜厚度、血清CA125均显著下降,差异均有统计学意义(P<0.01);子宫体积缩小,但与治疗前比较差异无统计学意义(P>0.05)。无严重不良反应发生。结论曼月乐能显著改善子宫腺肌症患者的症状体征,且不良反应相对较小。
Objective To observe the clinical efficacy of levonorgestrel-releasing intrauterine system (Mirena) in the treatment of adenomyosis. Methods Twenty-seven patients with adenomyosis treated with Mirena were selected from June 2013 to August 2015 in our hospital. The patients were followed up for 1 year. The menstruation, uterus, serum CA125 and related adverse reactions were observed before and after treatment. Results Compared with before treatment, Cox dysmenorrhea symptoms scale (CMSS), menstrual blood loss (PBAC) score, endometrial thickness and serum CA125 were significantly decreased at 3, 6, and 12 months after treatment (P <0.01). The uterus volume was reduced, but there was no significant difference between before and after treatment (P> 0.05). No serious adverse reactions occurred. Conclusion Mirena can significantly improve the symptoms and signs of patients with adenomyosis, and the adverse reaction is relatively small.